Subscribe To
NERV / Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates
NERV News
By Seeking Alpha
August 23, 2023
Minerva Neurosciences: There's Probably Time For One More Rally
Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private plac more_horizontal
By Zacks Investment Research
June 9, 2023
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In additio more_horizontal
By Seeking Alpha
May 19, 2023
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal more_horizontal
By GlobeNewsWire
May 8, 2023
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on more_horizontal
By Seeking Alpha
March 8, 2023
Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy more_horizontal
By Zacks Investment Research
December 29, 2022
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizo more_horizontal
By Seeking Alpha
November 9, 2022
Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Geoff Race - President Re more_horizontal
By InvestorPlace
August 24, 2022
Billionaire Steven Cohen Just Made a Big Bet on Minerva Neurosciences (NERV) Stock
Shares of Minerva Neurosciences (NASDAQ: NERV ) are soaring higher by over 70% following a purchase by Steve Cohen's Point72 Asset Management and th more_horizontal